Losartan and candesartan, which are angiotensin II type 1 receptor (AT1R) blockers, and enalapril, an angiotensin-converting enzyme (ACE) inhibitor, were able to promote beneficial effects against DR progression in animal models of diabetes due to the prevention of oxidative stress, inflammation, and vascular damage [187]. Here, ACE is linked to diabetes mellitus.